Oncology and Hematology

17-32 of 625

Venetoclax and Palbociclib in AML: Exploring New Findings
Venetoclax and Palbociclib in AML: Exploring New Findings
On the Frontlines of AML/ALL
Venetoclax and Palbociclib in AML: Exploring New Findings
- Ryan Quigley
- Jeffrey Tyner, PhD
- Melissa Stewart, PhD
Advancing Relapse Prediction in Pediatric AML Through Genomic MRD
Advancing Relapse Prediction in Pediatric AML Through Genomic MRD
On the Frontlines of AML/ALL
Advancing Relapse Prediction in Pediatric AML Through Genomic MRD
- Ryan Quigley
- Amanda Winters, MD, PhD
How Early Decisions in Upper GI Cancer Shape Long-Term Outcomes
How Early Decisions in Upper GI Cancer Shape Long-Term Outcomes
Project Oncology®
How Early Decisions in Upper GI Cancer Shape Long-Term Outcomes
- Alexandria May, PharmD, BCPS
- Sunnie Kim, MD
Understanding the Growing Burden of Early-Onset CRC
Understanding the Growing Burden of Early-Onset CRC
On the Frontlines of Colorectal Cancer
Understanding the Growing Burden of Early-Onset CRC
- Ryan Quigley
- Christopher Cann, MD
Decoding Co-Mutations in HR+, HER2- Metastatic Breast Cancer
Decoding Co-Mutations in HR+, HER2- Metastatic Breast Cancer
On the Frontlines of Metastatic Breast Cancer
Decoding Co-Mutations in HR+, HER2- Metastatic Breast Cancer
- Abirami Sivapiragasam
Chairperson’s Perspective: Evidence-Informed Clinical Decision-Making in HER2-Overexpressed and TROP2-Targeted NSCLC
Chairperson’s Perspective: Evidence-Informed Clinical Decision-Making in HER2-Overexpressed and TROP2-Targeted NSCLC
CME/CE
Chairperson’s Perspective: Evidence-Informed Clinical Decision-Making in HER2-Overexpressed and TROP2-Targeted NSCLC
0.25 credits
- Benjamin Levy, MD
0.25 credits
Neighborhood Archetypes and Patient Outcomes in Pediatric ALL and AML
Neighborhood Archetypes and Patient Outcomes in Pediatric ALL and AML
On the Frontlines of AML/ALL
Neighborhood Archetypes and Patient Outcomes in Pediatric ALL and AML
- Charles Turck, PharmD, BCPS, BCCCP
- Lena Winestone, MD, MSHP
Why Molecular Testing Matters in Non-Small Cell Lung Cancer
Why Molecular Testing Matters in Non-Small Cell Lung Cancer
Project Oncology®
Why Molecular Testing Matters in Non-Small Cell Lung Cancer
- Geoffrey Oxnard, MD
Integrating Molecular Testing into NSCLC Care
Integrating Molecular Testing into NSCLC Care
Project Oncology®
Integrating Molecular Testing into NSCLC Care
- Geoffrey Oxnard, MD
A New Era of Hope in Non-Small Cell Lung Cancer Care
A New Era of Hope in Non-Small Cell Lung Cancer Care
Project Oncology®
A New Era of Hope in Non-Small Cell Lung Cancer Care
- Geoffrey Oxnard, MD
Assessing G-CSF Prophylaxis with Sacituzumab Govitecan in mTNBC
Assessing G-CSF Prophylaxis with Sacituzumab Govitecan in mTNBC
Project Oncology®
Assessing G-CSF Prophylaxis with Sacituzumab Govitecan in mTNBC
- Charles Turck, PharmD, BCPS, BCCCP
- Kelly McCann, MD, PhD
- Gregory Vidal, MD, PhD
Smarter Screening for Non-Small Cell Lung Cancer
Smarter Screening for Non-Small Cell Lung Cancer
Project Oncology®
Smarter Screening for Non-Small Cell Lung Cancer
- Jobelle Baldonado, MD
Improving BCC Screening in Childhood Cancer Survivors Through Risk Modeling
Improving BCC Screening in Childhood Cancer Survivors Through Risk Modeling
AudioAbstracts
Improving BCC Screening in Childhood Cancer Survivors Through Risk Modeling
- Ryan Quigley
Cosibelimab Delivers Durable Responses in Advanced CSCC
Cosibelimab Delivers Durable Responses in Advanced CSCC
Project Oncology®
Cosibelimab Delivers Durable Responses in Advanced CSCC
Neoadjuvant Nivolumab With or Without Ipilimumab in Resectable CSCC
Neoadjuvant Nivolumab With or Without Ipilimumab in Resectable CSCC
Project Oncology®
Neoadjuvant Nivolumab With or Without Ipilimumab in Resectable CSCC
Recognizing High-Risk Profiles for NSCLC
Recognizing High-Risk Profiles for NSCLC
Project Oncology®
Recognizing High-Risk Profiles for NSCLC
- Jobelle Baldonado, MD